Predictors of Pulmonary Zygomycosis versus Invasive Pulmonary Aspergillosis in Patients with Cancer
Clinical Infectious Diseases2005Vol. 41(1), pp. 60–66
Citations Over TimeTop 10% of 2005 papers
Abstract
PZ in immunocompromised patients with cancer could potentially be distinguished from IPA on the basis of clinical and radiological parameters; prospective validation is needed.
Related Papers
- → Disseminated Zygomycosis in a Neutropenic Patient: Successful Treatment with Amphotericin B Lipid Complex and Granulocyte Colony-Stimulating Factor(1997)135 cited
- → Resistance to amphotericin B does not emerge during treatment for invasive aspergillosis(2002)42 cited
- → Cure of disseminated zygomycosis with cerebral involvement using high dose liposomal amphotericin B and surgery(2007)16 cited
- Experimental murine aspergillosis. Comparison of amphotericin B and a new polyene antifungal drug, SCH 28191.(1984)
- → Crossed immunoelectrophoresis of fungal antigens in tissues as a means of diagnosing systemic aspergillosis and zygomycosis in cattle(1993)5 cited